Knight Therapeutics (GUD) Stock Price, News & Analysis

Company Overview

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

Key Stats

• Today's Range: C$9.10 to C$9.22
• 50-Day Range: C$7.20 to C$9.14
• 52-Week Range: C$5.66 to C$9.25
• Volume: 87,084 shs
• Average Volume: 96,189 shs
• Market Capitalization: C$903.25 million
• P/E Ratio: 153.33
• Dividend Yield: N/A
• Price Target: C$9.50
• Consensus Rating: Buy

Knight Therapeutics Stock Analysis - MarketRank™

Knight Therapeutics scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Buy

Consensus Rating

Knight Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Knight Therapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Knight Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Knight Therapeutics is 152.17, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.57.

Price to Earnings Ratio vs. Sector

The P/E ratio of Knight Therapeutics is 152.17, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.83.

Price to Earnings Growth Ratio

Due to a projected decrease in earnings for Knight Therapeutics, their PEG ratio cannot be calculated.

Price to Book Value per Share Ratio

Knight Therapeutics has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for GUD.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Knight Therapeutics does not currently pay a dividend.

Dividend Growth

Knight Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for GUD on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Knight Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

45.62% of the stock of Knight Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

23.93% of the stock of Knight Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 6/09/2026

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:GUD
• CIK: N/A
• Web: www.gud-knight.com
• Phone: 514-484-4483
• Fax: N/A
• Employees: 725
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Knight Therapeutics: C$9.50
• High Price Target: C$9.50
• Low Price Target: C$9.50
• Potential Upside/Downside: +3.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): C$0.06
• Trailing P/E Ratio: 153.33
• Forward P/E Ratio: 91.14
• P/E Growth: -1013.5
• Net Income: -C$30.73 million
• Net Margins: 1.10%
• Pretax Margin: N/A
• Return on Equity: 0.73%
• Return on Assets: 0.51%

Debt

• Debt-to-Equity Ratio: 8.86
• Current Ratio: 2.32
• Quick Ratio: 1.79

Sales & Book Value

• Annual Sales: C$510.45 million
• Price / Sales: 1.77
• Cash Flow: C$2.39 per share
• Price / Cash Flow: 3.85
• Book Value: C$8.00 per share
• Price / Book: 1.15

Miscellaneous

• Outstanding Shares: 98,179,000
• Free Float: N/A
• Market Cap: C$903.25 million
• Optionable: Not Optionable
• Beta: -0.14